ALLYRNA key facts
- Developer of RNA-based biopharmaceutical technologies intended to accelerate therapeutic innovation in precision medicine.
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Aug 2025.
- Notable investors include Plaisance Capital, Gaorong Ventures, Jifeng Ventures, Qiji Investment.
- Status: Privately Held (backing).
Who backs ALLYRNA
4- ·Watch ALLYRNA: the Monday email on marks, rounds and moves
ALLYRNA funding rounds
No funding rounds for ALLYRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ALLYRNA investors
4 investors are on record for ALLYRNA, including Plaisance Capital, Gaorong Ventures, Jifeng Ventures and Qiji Investment.
About ALLYRNA
Developer of RNA-based biopharmaceutical technologies intended to accelerate therapeutic innovation in precision medicine. The company offers proprietary molecular platforms, cross-border research capabilities and targeted delivery systems, enabling clinical research institutions, drug developers and healthcare providers to advance treatment efficacy and expand access to next-generation therapies.
- Sector
- Healthcare
- HQ
- Hong Kong, Hong Kong
- Founded
- 2025
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ALLYRNA doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.